Rivaroxaban concentrations in acute stroke patients with different dosage forms.

<h4>Background</h4>The crushed-tablet rivaroxaban concentration has been previously reported to be lower than the non-crushed concentration. However, the rivaroxaban concentration of fine granules has not yet been investigated. The anticoagulation intensity of rivaroxaban with fine granu...

Full description

Bibliographic Details
Main Authors: Shinichi Wada, Manabu Inoue, Takayuki Matsuki, Takuya Okata, Masaya Kumamoto, Naoki Tagawa, Akira Okamoto, Toshiyuki Miyata, Masafumi Ihara, Masatoshi Koga, Kazunori Toyoda
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0214132
id doaj-f5da3a66e84d4b47893ca0a54c5815df
record_format Article
spelling doaj-f5da3a66e84d4b47893ca0a54c5815df2021-03-04T10:34:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-01143e021413210.1371/journal.pone.0214132Rivaroxaban concentrations in acute stroke patients with different dosage forms.Shinichi WadaManabu InoueTakayuki MatsukiTakuya OkataMasaya KumamotoNaoki TagawaAkira OkamotoToshiyuki MiyataMasafumi IharaMasatoshi KogaKazunori Toyoda<h4>Background</h4>The crushed-tablet rivaroxaban concentration has been previously reported to be lower than the non-crushed concentration. However, the rivaroxaban concentration of fine granules has not yet been investigated. The anticoagulation intensity of rivaroxaban with fine granules, tablets, and crushed tablets was compared in acute stroke patients to assess the efficacy of each form.<h4>Methods and findings</h4>Hospitalized patients over 75 years old with acute stroke who started taking rivaroxaban from April 2012 to September 2017 were included. Blood samples were drawn just before and 4 hours after taking rivaroxaban on a median of 5 days after treatment initiation for concentration measurements (C0h, C4h) based on an anti-factor Xa chromogenic assay. Of 114 patients (49 female, 83±5 years old), 97 had ischemic strokes, 9 had transient ischemic attacks, and 8 had intracerebral hemorrhages. Rivaroxaban was administered a median of 7 days after onset. Of these, 38 patients were given the 15 mg dose, and 76 were given the 10 mg dose. In the 15 mg dose group, C0h was significantly higher in the fine granule group than in the crushed tablet group, with no significant difference compared to the tablet group [C0h: 27.6±6.8 vs 4.0±4.1 (P = 0.01) vs. 33.3±25.2 ng/ml, (P = 0.51), respectively], as was C4h [223.0±66.6 vs 103.0±79.5 (P = 0.02) vs. 229.5±121.6 ng/ml (P = 0.88)]. In the 10 mg dose group, C0h was significantly higher in the fine granule group than in the crushed tablet group and comparable to that in the tablet group [23.2±7.9 vs 7.5±6.2 (P<0.01) vs 19.0±15.8 ng/ml, (P = 0.35)], as was C4h [150.7±85.4 vs 85.1±46.8 (P<0.01) vs 189.8±92.7 ng/ml (P = 0.18)].<h4>Conclusions</h4>The rivaroxaban concentration with fine granules was consistent with that in the tablet group and higher than that in the crushed tablet group.https://doi.org/10.1371/journal.pone.0214132
collection DOAJ
language English
format Article
sources DOAJ
author Shinichi Wada
Manabu Inoue
Takayuki Matsuki
Takuya Okata
Masaya Kumamoto
Naoki Tagawa
Akira Okamoto
Toshiyuki Miyata
Masafumi Ihara
Masatoshi Koga
Kazunori Toyoda
spellingShingle Shinichi Wada
Manabu Inoue
Takayuki Matsuki
Takuya Okata
Masaya Kumamoto
Naoki Tagawa
Akira Okamoto
Toshiyuki Miyata
Masafumi Ihara
Masatoshi Koga
Kazunori Toyoda
Rivaroxaban concentrations in acute stroke patients with different dosage forms.
PLoS ONE
author_facet Shinichi Wada
Manabu Inoue
Takayuki Matsuki
Takuya Okata
Masaya Kumamoto
Naoki Tagawa
Akira Okamoto
Toshiyuki Miyata
Masafumi Ihara
Masatoshi Koga
Kazunori Toyoda
author_sort Shinichi Wada
title Rivaroxaban concentrations in acute stroke patients with different dosage forms.
title_short Rivaroxaban concentrations in acute stroke patients with different dosage forms.
title_full Rivaroxaban concentrations in acute stroke patients with different dosage forms.
title_fullStr Rivaroxaban concentrations in acute stroke patients with different dosage forms.
title_full_unstemmed Rivaroxaban concentrations in acute stroke patients with different dosage forms.
title_sort rivaroxaban concentrations in acute stroke patients with different dosage forms.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2019-01-01
description <h4>Background</h4>The crushed-tablet rivaroxaban concentration has been previously reported to be lower than the non-crushed concentration. However, the rivaroxaban concentration of fine granules has not yet been investigated. The anticoagulation intensity of rivaroxaban with fine granules, tablets, and crushed tablets was compared in acute stroke patients to assess the efficacy of each form.<h4>Methods and findings</h4>Hospitalized patients over 75 years old with acute stroke who started taking rivaroxaban from April 2012 to September 2017 were included. Blood samples were drawn just before and 4 hours after taking rivaroxaban on a median of 5 days after treatment initiation for concentration measurements (C0h, C4h) based on an anti-factor Xa chromogenic assay. Of 114 patients (49 female, 83±5 years old), 97 had ischemic strokes, 9 had transient ischemic attacks, and 8 had intracerebral hemorrhages. Rivaroxaban was administered a median of 7 days after onset. Of these, 38 patients were given the 15 mg dose, and 76 were given the 10 mg dose. In the 15 mg dose group, C0h was significantly higher in the fine granule group than in the crushed tablet group, with no significant difference compared to the tablet group [C0h: 27.6±6.8 vs 4.0±4.1 (P = 0.01) vs. 33.3±25.2 ng/ml, (P = 0.51), respectively], as was C4h [223.0±66.6 vs 103.0±79.5 (P = 0.02) vs. 229.5±121.6 ng/ml (P = 0.88)]. In the 10 mg dose group, C0h was significantly higher in the fine granule group than in the crushed tablet group and comparable to that in the tablet group [23.2±7.9 vs 7.5±6.2 (P<0.01) vs 19.0±15.8 ng/ml, (P = 0.35)], as was C4h [150.7±85.4 vs 85.1±46.8 (P<0.01) vs 189.8±92.7 ng/ml (P = 0.18)].<h4>Conclusions</h4>The rivaroxaban concentration with fine granules was consistent with that in the tablet group and higher than that in the crushed tablet group.
url https://doi.org/10.1371/journal.pone.0214132
work_keys_str_mv AT shinichiwada rivaroxabanconcentrationsinacutestrokepatientswithdifferentdosageforms
AT manabuinoue rivaroxabanconcentrationsinacutestrokepatientswithdifferentdosageforms
AT takayukimatsuki rivaroxabanconcentrationsinacutestrokepatientswithdifferentdosageforms
AT takuyaokata rivaroxabanconcentrationsinacutestrokepatientswithdifferentdosageforms
AT masayakumamoto rivaroxabanconcentrationsinacutestrokepatientswithdifferentdosageforms
AT naokitagawa rivaroxabanconcentrationsinacutestrokepatientswithdifferentdosageforms
AT akiraokamoto rivaroxabanconcentrationsinacutestrokepatientswithdifferentdosageforms
AT toshiyukimiyata rivaroxabanconcentrationsinacutestrokepatientswithdifferentdosageforms
AT masafumiihara rivaroxabanconcentrationsinacutestrokepatientswithdifferentdosageforms
AT masatoshikoga rivaroxabanconcentrationsinacutestrokepatientswithdifferentdosageforms
AT kazunoritoyoda rivaroxabanconcentrationsinacutestrokepatientswithdifferentdosageforms
_version_ 1714805542330826752